As it enters the 2026 fiscal year, Agilent Technologies is sharpening its strategic focus on technological specialization and operational efficiency. The company aims to strengthen its position in core markets, with significant investor attention directed toward the explosive growth of its contract development and manufacturing organization (CDMO) segment.
Operational Excellence and Environmental Solutions
A key component of Agilent’s strategy is its company-wide “Ignite” operating system, designed to enhance execution quality and accelerate growth. This initiative was a central topic during management’s presentation at the J.P. Morgan Healthcare Conference in mid-January.
Complementing this operational push, the company is targeting high-demand analytical niches. Just yesterday, Agilent released a practical guide for laboratories analyzing per- and polyfluoroalkyl substances (PFAS) in water samples. This move directly addresses a critical need in environmental and clinical analytics, where labs face substantial technical hurdles due to extremely low regulatory limits for these chemicals.
CDMO Division Drives Performance
The standout performer for Agilent has been its CDMO business. In the fourth quarter of the last fiscal year, this division reported core growth exceeding 40%. Looking ahead, management forecasts growth in the mid-teens percentage range for 2026.
Should investors sell immediately? Or is it worth buying Agilent?
This anticipated expansion is supported primarily by capacity increases at its subsidiary, BIOVECTRA, coupled with sustained high demand related to GLP-1 active pharmaceutical ingredients. A key question for investors is whether the segment can maintain its remarkable momentum throughout the coming year.
Financial Snapshot and Regional Outlook
For its fourth quarter 2025, Agilent posted earnings of $1.59 per share on revenue of $1.86 billion. The company’s market capitalization recently stood at approximately $38.1 billion. Investors can expect the next financial update with the release of Q1 2026 results, scheduled for February 25.
Geographically, the company maintains a long-term optimistic view of the Chinese market, expecting mid- to high-single-digit growth. However, for the current 2026 fiscal year, leadership has moderated near-term expectations, projecting essentially flat revenue development in the region.
Ad
Agilent Stock: Buy or Sell?! New Agilent Analysis from January 31 delivers the answer:
The latest Agilent figures speak for themselves: Urgent action needed for Agilent investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 31.
Agilent: Buy or sell? Read more here...
